Booker v. Pfizer, Inc.

E-Law Admin/ Januar 30, 2017/ Arzneimittelrecht Schweiz/ 0Kommentare

Booker v. Pfizer, Inc., 16-1805

In a qui tam action against a pharmaceutical defendant in federal district court, on behalf of the U.S., more than two dozen individual states, and the District of Columbia, and asserting that despite a previous settlement, defendant had continued to engage in conduct involving their drugs that is prohibited by the False Claims Act (FCA), 31 U.S.C. sections 3729 et seq. and state analogues, the district court’s grant of summary judgment, and certain of the district court’s intervening discovery rulings is affirmed where: 1) the complaint fails to state a claim for relief; and 2) there was no error in the district court’s discovery rulings.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/01/30



  • United States First Circuit


e-Law Trainer

Share this Post

Hinterlasse einen Kommentar